BioCentury
ARTICLE | Company News

Neurocrine, Sibia deal

April 15, 2013 7:00 AM UTC

NBIX received a non-exclusive license to use SIBI's transcription-based assay patents against a specific target. In exchange, SIBI receives access to NBIX's compound library to discover compounds dire...